Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

5.115 -0.015 (-0.29%)

Delayed Quote Updated: 3:42 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

44 Stocks Moving In Tuesday's Mid-Day Session ↗

March 01, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 01, 2022

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 102.3% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3...

Via Benzinga

27 Stocks Moving in Monday's Pre-Market Session ↗

March 01, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6...

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Expert Ratings For Atea Pharmaceuticals ↗

January 06, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) has observed the following analyst ratin...

Via Benzinga

Atea Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2022

Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement....

Via Benzinga

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗

February 11, 2022

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Via Investor's Business Daily

NASDAQ:AVIR Investor Notice: Investigation over Possible Securities Laws Violations by Atea Pharmaceuticals, Inc. ↗

February 02, 2022

San Diego, CA -- (SBWIRE) -- 02/02/2022 -- Atea Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation

January 12, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Earnings Scheduled For November 11, 2021 ↗

November 11, 2021

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗

January 06, 2022

Upgrades For Canada Goose Holdings Inc (NYSE:

Via Benzinga

7 Pharmaceutical Stocks That Could Make You Rich ↗

January 06, 2022

Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich

Via InvestorPlace

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗

December 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...

Via Benzinga

After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗

December 15, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 18, 2021

Gainers NeuroOne Medical Tech (NASDAQ:NMTC...

Via Benzinga

What 5 Analyst Ratings Have To Say About Atea Pharmaceuticals ↗

November 18, 2021

Over the past 3 months, 5 analysts have published their opinion on Atea Pharmaceuticals (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2021 ↗

November 18, 2021

Upgrades Macquarie upgraded the previous rating for ZTO Express (Cayman) Inc (NYSE:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 17, 2021

Gainers EyePoint Pharmaceuticals (NASDAQ:EYP...

Via Benzinga

61 Biggest Movers From Yesterday ↗

November 18, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) shares climbed 154.7% to close at $38.20 on Wednesday after the company priced its IPO at $15 per share. Braze, Inc. (NASDAQ: BRZE) jumped...

Via Benzinga

Topics Initial Public Offering

42 Stocks Moving In Wednesday's Mid-Day Session ↗

November 17, 2021

Gainers Sono Group N.V. (NASDAQ: SEV) shares jumped 66% to $24.90 after the company priced its IPO at $15 per share. EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares climbed...

Via Benzinga

Topics Initial Public Offering

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 17, 2021

Gainers Rockwell Medical (NASDAQ:RMTI) shares rose 47.27% to $0.71 during Wednesday's pre-market session. The company's market cap stands at $66.5 million. The...

Via Benzinga

Why Atea Pharmaceuticals Stock Is Sinking Today ↗

November 17, 2021

Roche calls it quits on the duo's attempt to develop an oral COVID-19 therapy.

Via The Motley Fool

Atea Shares Plunge As Roche Culls Partnership To Develop COVID-19 Pill ↗

November 17, 2021

Roche Holdings AG (OTC: RHHBY) has ended a partnership with Atea Pharmaceuticals Inc (NASDAQ: AVIR) to jointly develop a COVID-19 antiviral pill, a month...

Via Benzinga

The Daily Biotech Pulse: Atea Sinks On Termination Of Roche Contract, Pfizer CFO To Retire, GSK-Vir Bag $1B Contract To Supply COVID Antibody Treatment ↗

November 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Atea Announces Termination of Strategic Collaboration With Roche Atea...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 17, 2021

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

25 Stocks Moving in Wednesday's Pre-Market Session ↗

November 17, 2021

Gainers 17 Education & Technology Group Inc. (NASDAQ: YQ) rose 283.5% to $3.16 in pre-market trading. 17 Education & Technology, earlier during the month, reported a $10...

Via Benzinga

Atea Pharma Stock Collapses As Roche Pulls The Plug On Pfizer-Rivaling Covid Pill ↗

November 16, 2021

Roche and Atea's partnership will end in February.

Via Investor's Business Daily

Atea Pharmaceuticals Inc (AVIR) Q3 2021 Earnings Call Transcript ↗

November 12, 2021

AVIR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals? ↗

November 05, 2021

Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.